Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

International Stem Cell (ISCO) Gross Profit (2016 - 2025)

Historic Gross Profit for International Stem Cell (ISCO) over the last 17 years, with Q3 2025 value amounting to $1.3 million.

  • International Stem Cell's Gross Profit rose 962.66% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 1110.2%. This contributed to the annual value of $5.3 million for FY2024, which is 1547.31% up from last year.
  • According to the latest figures from Q3 2025, International Stem Cell's Gross Profit is $1.3 million, which was up 962.66% from $1.5 million recorded in Q2 2025.
  • International Stem Cell's 5-year Gross Profit high stood at $1.5 million for Q2 2025, and its period low was $1.0 million during Q3 2022.
  • Over the past 5 years, International Stem Cell's median Gross Profit value was $1.2 million (recorded in 2024), while the average stood at $1.2 million.
  • As far as peak fluctuations go, International Stem Cell's Gross Profit plummeted by 3060.55% in 2021, and later soared by 4191.03% in 2024.
  • Quarter analysis of 5 years shows International Stem Cell's Gross Profit stood at $1.1 million in 2021, then increased by 16.79% to $1.3 million in 2022, then decreased by 20.71% to $1.0 million in 2023, then skyrocketed by 41.91% to $1.5 million in 2024, then fell by 9.27% to $1.3 million in 2025.
  • Its Gross Profit was $1.3 million in Q3 2025, compared to $1.5 million in Q2 2025 and $1.1 million in Q1 2025.